H2020Индивидуална стипендия2020–2022

GAMBBa · Gene-activated AntiMicrobial Biomaterials for Bone regeneration

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2020-09-01 → 2022-08-31
Финансиране от ЕС: 184 591 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Биоматериали с антибактериални наночастици и генетични компоненти се тестват за едновременно унищожаване на бактерии и възстановяване на костна тъкан. Разработката помага за подобряване на лечението при остеомиелит, при който инфекцията затруднява зарастването на костта.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Gene-activated AntiMicrobial Biomaterials for Bone regeneration

The overarching research aim of this proposal is to address the clinical problem of osteomyelitis, i.e. bone infection, by developing a biomaterial scaffold that eliminates bacteria while regenerating bone simultaneously. For that, the biomaterial scaffold combines, for the first time, the controlled delivery of osteoanabolic genetic cargo for bone healing with non-antibiotic antimicrobial nanoparticles (a-NPs). During the project, I assessed the effect of various metal ions, such as zinc and copper, on the toxicity of most common models of bacteria, gram-positive Staphylococcus aureus (S.aureus) and gram-negative Escherichia coli (E.coli), and viability of human mesenchymal stem cells (hMSCs) in 2D cultures showing that the dosages higher than 5 mM result in bacterial lysis. These antimicrobial ions were then incorporated into inorganic materials: nanohydroxyapatite (a-nHA) and bioglass (a-BG). I showed that the incorporation of Cu-BG into collagen scaffolds significantly reduces the attachment of S.aureus, equipping the biomaterial scaffold with antimicrobial properties. During the project, I evaluated various genetic cargoes showing that antagomiR-138 exhibits favourable osteogenic properties stimulating human mesenchymal stem cells to differentiate into bone cells. I have also assessed the osteogenic potential of miR-26a and antagomiR-133a in vitro. The genetic cargoes were further incorporated into collagen scaffolds and assessed in vivo. The antagomiR-138 was incorporated into antimicrobial scaffolds, which contained Cu-BG. Its osteogenic and angiogenic potential was confirmed using the ex ovo embryo chick model. Based on the results, the scaffolds combining antimicrobial nanoparticles with osteogenic genetic cargoes might be a potential solution for treating infected bone tissue.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Osteomyelitis, i.e. bone infection, combined with the alarming rise in antibiotic resistance globally, is currently regarded as the most devastating clinical complication when attempting to repair bone defects. This project tackles these major challenges of modern bone tissue engineering by developing a novel technology with dual osteogenic and antimicrobial action i.e. regenerative scaffolds that can eliminate bacterial infection while simultaneously providing a bioactive environment for bone growth. The specific goal of this research proposal is to develop and evaluate a new, innovative and effective treatment for osteomyelitis by combining non-antibiotic antimicrobial nanoparticles with gene-activated scaffolds for bone regeneration. Osteoconductive collagen-nanohydroxyapatite scaffolds with proven bone-healing potential will be functionalised for the sustained delivery of genetic cargoes to improve tissue repair, i.e. plasmid DNA (pBMP-2) and microRNA (antagomiR-133a), using novel technologies pioneered at Prof O’Brien’s Lab in the Royal College of Surgeons in Ireland. The project will also study the incorporation of metal-ions, an innovative alternative to traditional antibiotics, into scaffolds and bioglasses developed at Prof Boccaccini’s Lab at Friedrich-Alexander-Universität Erlangen-Nürnberg. Diligently supervised by Profs. O’Brien and Boccaccini, and guided by a Personal Career Development Plan, I will develop complementary skills in project management, entrepreneurship, commercialisation, leadership and profile enhancement. Acquiring advanced research competences and complementary skills will allow me to mature as an independent scientist, enhancing my professional visibility, capacity and competitiveness in the field of regenerative medicine. This Fellowship will significantly contribute to the achievement of my long-term career goal, which is becoming an independent scientist leading my own group focused on novel biomaterial research and development.

Оригинален текст от CORDIS (на английски).

Участници

ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2КоординаторИрландия